Icotinib vs Osimertinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
Icotinib
Marketed by Betta Pharmaceuticals Co.
NCT01040780 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 200 participants assigned to icotinib and 199 to gefitinib, and its primary endpoint was the clinical measure of progression-free survival. Although the reported median favored icotinib, the statistical significance of the primary comparison is not stated, so the result is unclear rather than definitively positive.
Next expected readout: October 2030 · NCT07458919 (registry estimate)
Reported efficacy
Progression Free Survival (12 months): Primary endpoint, PFS (CONVINCE trial): icotinib 11.2 months vs cisplatin/pemetrexed+pemetrexed maintenance 7.9 months; HR 0.61 (95% CI 0.43-0.87), p=0.006 (met)
Result source: NCT01719536
Osimertinib · Tagrisso
Marketed by AstraZeneca
NCT02151981 · Phase 3 · completed
The trial was randomized and actively controlled, with 279 patients receiving osimertinib and 140 receiving platinum-based chemotherapy, but treatment assignment was not blinded. Its primary clinical endpoint, investigator-assessed progression-free survival, favored osimertinib significantly (hazard ratio 0.30; p<0.001), supporting moderate-strength evidence rather than the strongest level because the study was open-label.
Next expected readout: November 2026 · NCT05998993 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6) (met)
Result source: NCT02151981
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Icotinib | Osimertinib |
|---|---|---|
| PFS, median | 4.6 vs 3.4vs GefitinibNCT010407801 other result
| 19.5 vs 22.0vs GefitinibNCT028568931 other result
|
| OS, median | 13.3 vs 13.9vs GefitinibNCT01040780 | —Not posted · NCT05015608 |
| ORR | —Not posted · NCT04206072 | 76%bNCT02789345 |
| Duration of response, median | —Not posted · NCT04206072 | 13.4bNCT02789345 |
PFS, median
- Icotinib
- 4.6 vs 3.4vs GefitinibNCT01040780
1 other result
- 11.2 vs 7.9 NCT01719536
- Osimertinib
- 19.5 vs 22.0vs GefitinibNCT02856893
1 other result
- 11.0 NCT02789345
OS, median
- Icotinib
- 13.3 vs 13.9vs GefitinibNCT01040780
- Osimertinib
- —Not posted · NCT05015608
ORR
- Icotinib
- —Not posted · NCT04206072
- Osimertinib
- 76%bNCT02789345
Duration of response, median
- Icotinib
- —Not posted · NCT04206072
- Osimertinib
- 13.4bNCT02789345
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Icotinib: 3 of 4 rows · Osimertinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Icotinib | Osimertinib |
|---|---|---|
| Dropout rate | 0.5%a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result0% NCT02264210 · Phase 2 · registry result, not featured evidence | 62.3%b NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results100%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 77.3%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result— NCT02264210 · Phase 2 · registry result, not featured evidence | 3.8%b NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results0%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 4.5%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 6.5%a NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more result6.3% NCT02264210 · Phase 2 · registry result, not featured evidence | 17%b NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more results33.3%Arm A: Ramucirumab + Osimertinib NCT02789345 · Phase 1 · registry result, not featured evidence · combination 36.4%Cohort A: Ramucirumab + Osimertini NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a rash 40.5% diarrhea 21.5% pain 18% NCT01040780 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 1 more resultrash 39.7% (placebo 0%) diarrhoea 20.6% (placebo 0%) pain 11.1% (placebo 0%) NCT02264210 · Phase 2 · registry result, not featured evidence | b diarrhea 50.9% dry skin 41.5% weight loss 35.8% NCT02856893 · Phase 2 · registry result, not featured evidence show 2 more resultscough 100% diarrhoea 100% arthralgia 66.7% NCT02789345 · Phase 1 · registry result, not featured evidence · combination diarrhoea 63.6% hypertension 63.6% decreased appetite 40.9% NCT02789345 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Icotinib
Osimertinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Icotinib's landscape · Osimertinib's landscape